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Abstract: Nicotinamide (NA), a water-soluble vitamin B3, has been shown to exert cellular-protective
effects against reactive oxygen species (ROS). In order to improve the cellular-protective effects of NA,
we synthesized a novel compound, nicotinyl–isoleucine–valine–histidine (NA–IVH), by combining
NA with jellyfish peptides’ IVH. In the present study, we examined the cellular-protective effects
of the novel synthetic nicotinyl-peptide, NA–IVH. We found that NA–IVH enhances the radical
scavenging activity with a robust increase of the nuclear factor (erythroid-derived 2)-like factor (Nrf2)
expression in human HaCaT keratinocytes. In addition, NA–IVH protected the cells from hydrogen
peroxide (H2O2)-induced cell death. Interestingly, NA–IVH exhibited an improved wound-healing
effect in a high glucose condition, possibly through the regulation of reactive oxygen species (ROS).
Collectively, our results imply that a novel nicotinyl-peptide, NA–IVH, has a wound-healing effect in
a hyperglycemic condition, possibly by modulating excessive ROS.
Keywords: nicotinamide; isoleucine-valine-histidine; antioxidant; nuclear factor (erythroid-derived
2)-like factor; wound-healing
1. Introduction
Wound-healing is a multidimensional healing process involving various physiological regulations,
by which the skin responses to wounds in order to repair itself. It is believed that once the skin
is wounded, it begins a set of intrinsic responses, in which the skin undergoes various phases,
including the hemostasis, inflammatory, and proliferative phases [1]. After a wound has been
made, the primary response involves the inhibition of further rupture, thereby minimizing the loss
of blood. During the second phase, the damaged tissues, bacteria, and pathogens are removed by the
inflammatory cells [2]. However, during the inflammatory phase, large amounts of reactive oxygen
species (ROS) are produced by the NADPH oxidase, an enzyme highly expressed in inflammatory
cells [3,4]. Together, it has been reported that antimicrobial peptides also play a critical role in the
wound healing processes [5–7].
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It has been suggested that when present in an adequate quantity, ROS play various roles in
the normal physiological wound-healing process, including bacterial killing and epithelization,
and the beneficial role of ROS in the wound-healing process is further supported by a previous
finding, which has suggested that wound-healing is impaired in the hypoxia condition [8]. However,
excessive ROS induction has been linked with the activation of pro-apoptotic proteins, leading to
cell death and necrosis [9]. For instance, an elevation of ROS levels was observed in the chronic and
non-healing wounds in vivo, suggesting a possibility that excessive ROS might be detrimental to the
wound-healing process [4]. Moreover, excessive levels of ROS have been linked with hyperglycemic
complications, such as diabetic ulcers, and several efforts against increasing the prevalence of such
disorder have been made through the regulation of excessive ROS levels [10,11]. Altogether,
the homeostatic control of the cellular ROS levels may play a pivotal role in the regulation of the
wound-healing process [12].
Nicotinamide (NA), a water-soluble vitamin B3, has been reported to enhance DNA repair
and prevent ultraviolet (UV)-induced immunosuppression, thereby protecting the skin against
photocarcinogenesis caused by te ROS generated by the UV [13–19]. Moreover, in vitro and in vivo
studies have demonstrated that NA possesses antioxidant properties as well [20,21]. The NA has been
incorporated into topical ointments targeted for a wide range of dermatological disorders [22–24].
Although there are concerns regarding the worldwide increase of the gelatinous biomass of jellyfish,
an increasing number of results also showed that the jellyfish could be used as a new source of marine
drugs [25,26]. In this regard, we isolated a peptide, isoleucine–valine–histidine (IVH), from a jellyfish
and synthesized a novel molecule, NA–IVH, by conjugating NA to IVH, in orer to enhance the
cellular-protective effects of NA. The IVH peptides that have been extracted from a jellyfish and that
has exhibited several beneficial effects, including the antioxidant function [27–32].
In the present study, we analyzed the potential physiological effects of the synthetic NA–IVH in
the human HaCaT keratinocytes.
2. Results
2.1. Synthesis of Nicotinyl–Isoleucine–Valine–Histidine (NA–IVH)
We analyzed the extracts of jellyfish using preparative gel electrophoresis and RP-high-
performance liquid chromatography (HPLC) to determine the IVH as a bioactive and
effective compound. NA–IVH was synthesized by the general hydroxybenzotriazole (HOBt)-
diisopropylcarbodiimide (DIC)-mediated solid-phase peptide synthesis (SPPS) protocol [33], and was
purified using high-performance liquid chromatography (HPLC). The purity of the NA–IVH was
increased up to 95% after the HPLC purification. The molecular weight and chemical structure
were determined by a matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) mass
spectrometry assay (Figure 1A,B).
2.2. Cytotoxicity and Antioxidant Activity of NA–IVH
To examine the cytotoxic effect of NA–IVH, we performed a 3-(4,5-dimethylthiazol-2-yl)-2,
5-diphenyltetrazoliumbromide (MTT) assay using HaCaT cells. The cells were treated with NA–IVH
at different doses (0, 1, 5, 10, and 20 µM) for 24 h. After the treatment, the cell culture media was
replaced with media containing 100 µL of MTT solution (0.5 mg/mL in DMSO), and was further
incubated for 2 h until the MTT formazan was precipitated. As shown in Figure 2A, the NA–IVH
treatment at varying concentrations did not demonstrate the cytotoxicity in HaCaT cells. To examine
the antioxidant activity of NA–IVH, the DPPH (2,2-diphenyl-1-picrylhydrazyl) radical scavenging
assay was used by adding 0.1 mM of a DPPH solution to each sample for 30 min before the absorbance
measurement. Our data demonstrated that the NA–IVH at the concentration of 1 µM induced the
most efficient antioxidant activity (Figure 2B). In response to the accumulating ROS, cells require
an efficient antioxidant activity achieved by the activity of ROS-detoxifying enzymes and proteins.
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To determine the antioxidant function, the expressions of the antioxidant genes were examined upon
the NA–IVH treatment. As shown in Figure 2C, the NA–IVH treatment for 24 h increased the Nrf2
expression. Next, we examined the downstream genes of Nrf2, including heme oxygenase-1 (HO-1),
superoxide dismutase 1 and 2 (SOD 1 and 2), Catalase (CAT), and glutathione peroxidase 1 (GP×1)
(Figure 2D–H). Interestingly, all of the genes examined showed a significant increase, and the increase
was more distinctive than that of the original form of NA (Figure 2C–H). These data indicate that
NA–IVH has the potential to regulate oxidative stress through the activation of antioxidant genes.
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Figure 2. NA–IVH increases expression of antioxidant genes in HaCaT cells. (A) Dose-dependent cell
viability of NA–IVH was assayed using MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium
Bromide). (B) Reactive oxygen species (ROS) scavenging effect of NA–IVH. (C–H) Expressions of
anti-oxidant genes were measured using real-time quantitative PCR. The results are expressed as mean
± SEM (* p < 0.05, ** p < 0.01, *** p < 0.001, on -way analysis of varianc (ANOVA), or Student’s t-test).
2.3. Protective Role of NA–IVH on ROS-Induced Cytotoxicity
Next, we examined the antioxidant role of NA–IVH upon the treatment of 1 mM of H2O2.
HaCaT cells were pretreated with either dimethyl sulfoxide (DMSO), NA, NA–IVH, or n-acetyl cysteine
(NAC) for 2 h before H2O2 introduction. Methylene blue staining and MTT assay were performed
after H2O2 treatment for 21 h. The cell death induced by H2O2 was significantly reduced by the
pretreatment of NA–IVH (Figure 3A,B). Furthermore, the pretreatment of NA–IVH markedly reduced
the H2O2-induced ROS generation in the HaCaT cells as measured by 2’,7’ –dichlorofluorescin diacetate
(DCFDA), suggesting NA–IVH as a potential ROS-scavenging molecule (Figure 3C,D). Intriguingly,
NA–IVH also showed a more robust antioxidant activity compared to that of NA, implying that the
conjugation between NA and IVH might enhance its original antioxidant function (Figure 3).
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Figure 3. Antioxidant role of NA–IVH in HaCaT cells. (A) Antioxidant effect of NA–IVH in the presence
of H2O2 was monitored using methylene blue staining. (B) Effect of NA–IVH on cell viability in the
presence of H2O2. (C) ROS scavenging effect of NA–IVH in the presence of H2O2. (D) Fluorescence
intensity (%) from (C). The results are expressed as mean ± SEM (* p < 0.05, ** p < 0.01 against vehicle
with H2O2 treatment, one-way ANOVA). Scale bar 0.5 mm.
2.4. Improved Wound-Healing Effect of NA–IVH in High Glucose Condition
A recent study demonstrated that the Nrf2 expression might be associated with the wound- aling
process in a diabetic mouse model, suggesting a potential contribution of NA–IVH in the wound-
healing process in a high glucose (HG) condition, given that NA–IVH increased the expression of
Nrf2 [34]. Hence, we performed a wound-healing assay, in which the HaCaT cells cultured in HG
condition were wounded prior to a treatment of either DMSO, NA, NA–IVH, or epidermal growth
factor (EGF) for 24 h. Although the cells in the HG media showed a delayed wound closure compared
to that of the cells in the low-glucose (LG) media, the cells treated with NA–IVH in the HG media
showed an accelerated wound closur when compared to that of the vehicle-treated (Figure 4A,B).
Moreover, it is noteworthy that NA–IVH in th HG ondition showed a greater wound-healing efficacy,
demonstrated by a narrower wound gap than that of the NA treated cells. This result indicates that
NA–IVH is capable of accelerating the wound-healing of the HaCaT cells in the diabetic condition.
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Figure 4. NA–IVH accelerates wound-healing in a high glucose (HG) condition. (A) Wound-healing
effect of either DMSO, NA, NA–IVH or epidermal growth factor (EGF) in low (5.5 mM) or high (50 mM)
glucose condition. LG—low glucose; HG—high glucose. (B) Wound-healing (%) was measured in
either a low (5.5 mM) or high (50 mM) glucose condition. The results are expressed as mean ± SEM
(*** p < 0.001, one-way ANOVA). Scale bar 0.5 mm.
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3. Discussion
NA has been well-recognized as a cellular protective molecule for its antioxidant properties [20,21],
and efforts to produce a novel NA peptide that retains the beneficial effects of NA with a greater
potency in carrying out its effects have been made [35]. In the current study, we synthesized a novel
nicotinyl-derivative, NA–IVH, which retains the antioxidant and wound-healing properties of NA
with a greater efficacy. It has been reported that the Nrf2 expression is modulated by the ROS in
keratinocytes [36–40]. The Nrf2 is widely known for its orchestration of the transcription of endogenous
antioxidant genes via an antioxidant response element (ARE) [41]. In this study, we found that Nrf2
was increased upon NA–IVH treatment and led to the activation of its downstream antioxidant
genes, including HO-1, SOD1 and 2, CAT, and GPx1 in HaCaT cells (Figure 2), suggesting that
the antioxidant and anti-cytotoxic effect of NA–IVH could at least partially come from the direct
regulation of antioxidant genes. In addition, Nrf2 has been indicated as a target gene of keratinocyte
growth factor (KGF), and is upregulated in the wounded epidermis [42–45], indicating a possible
involvement of Nrf2 in the wound-healing process on the skin. However, recent evidence demonstrated
that Nrf2-mediated gene expression in keratinocytes is unnecessary for wound-healing, at least
under normal conditions [43]. Hence, whether Nrf2 is required for wound-healing under varying
circumstances requires further studies.
Interestingly, Long et al. demonstrated that the pharmacological activation of Nrf2 pathway
significantly improved diabetic wound-healing, suggesting a possible involvement of the Nrf2
activators as treatments for diabetic skin ulcers [34]. Moreover, mice lacking Nrf2 demonstrated
a slowed wound-healing process, due to the deprivation of efficient antioxidant activity [34].
Environmental challenges, such as UV irradiation, toxic chemicals, and mechanical wounding, result in
increased reactive oxygen species (ROS), inflammation, skin aging, and cancer development [46].
Although ROS are generated during the normal metabolic processes and are required for regular
cellular signaling, excessive ROS levels are suggested to cause severe cellular damage, leading to
disease development [46,47]. Hence, the development of an efficient ROS defensive mechanism on the
skin has been of great interest. Although other studies suggest that presence of ROS is supportive of
wound-healing [5,35], the excessive production of ROS leads to oxidative stress, causing severe cell
damage and cell death [4]. Hence, the homeostatic regulation of ROS might be essential for an efficient
wound-healing process. Therefore, a novel NA–IVH having an antioxidant and wound-healing
function could work as homeostatic component in the wound-healing process.
Wound closure upon NA and NA–IVH treatment in a low glucose (LG) condition did not
demonstrate a significant difference between the two. However, we found that the accelerated
wound-healing process when NA and NA–IVH were introduced to wounded cells grown in a high
glucose (HG) condition (Figure 4). Therefore, our study demonstrates that a novel nicotinyl-peptide,
NA–IVH, possesses a wound-healing effect in the hyperglycemic condition, possibly by modulating
excessive ROS.
4. Materials and Methods
4.1. Synthesis and Purification of Nicotinic Acid–IVH
Amino acids and nicotinic acid were coupled to the resin by general 1-hydroxybenzotriazole-
diisopropylcarbodiimide (HOBt-DIC) mediated solid-phase peptide synthesis (SPPS) protocol [33] and
then purified by reverse-phase HPLC (Waters, MA, USA; pump 600E, UV-484 detector, Gemini RP-C18
column 250 × 21.2 mm) in a gradient of acetonitrile in 0.1% trifluoroacetic acid. A MALDI-TOF mass
spectrometry assay was performed to determine the quality of the synthetic NA–IVH. All of the
mass spectrometry (MS) or MS/MS experiments were performed on a mass spectrometer (Q-Star XL,
AB Sciex, Foster City, CA, USA) with a turboionspray source. The electrospray ionization (ESI) ion
source parameters were a spray voltage 5.0 kV, curtain gas 25 L/min, and nebulizer gas 20 L/min.
Synthetic peptides were confirmed for the molecular weights in full scan mode, and then sequenced
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by MS/MS scans. The collision energies were varied from 20 to 40 to efficiently get the fragments.
The results were manually interpreted by Analyst QS 1.1 with Bioanalyst extensions (or all MS or
MS/MS experiments followed the methods described in previous report [35]).
4.2. Cell Culture and Reagents
Human keratinocytes, HaCaT cells, obtained from Dr. Fusenig, Deutsches Krebsforschungszentrum,
Heidelberg, Germany [48], were grown in Dulbecco’s modified Eagle’s medium (DMEM, low glucose,
Hyclone, Logan, UT, USA) containing a 10% heat inactivated fetal bovine serum (FBS) at 37 ◦C in 5%
CO2. The high glucose (HG) condition DMEM was made with an addition of 1 M glucose or 0.5 M
mannitol to Dulbecco’s modified Eagle’s medium (DMEM, low glucose, Hyclone, Logan, UT, USA)
in order to produce high glucose in the cell culture system or to adjust osmosis, respectively [49].
Epidermal growth factor (EGF), n-acetyl cysteine (NAC), H2O2, glucose, and mannitol were purchased
from Sigma-Aldrich (St. Louis, MO, USA).
4.3. Cell Viability Assay
An MTT assay was performed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide
(MTT) based cell viability and proliferation Kit 1 (Sigma-Aldrich, St. Louis, MO, USA), following the
suggested protocol. In brief, 3 × 104 cells were seeded in 96-well microplates and cultured for 24 h
prior to treatment. The cells were treated with DMSO, different concentrations of NA–IVH (0, 1, 5, 10,
and 20 µM), or N-Acetyl cysteine (NAC, 1 mM), with/without 1 mM H2O2, and incubated for 24 h,
then, the media was replaced with 100 µL of MTT solution (0.5 mg/mL in DMEM), in which the cells
were incubated at 37 ◦C for 4 h. The MTT solution was removed and MTT formazan dissolved in
100 µL of dimethyl sulfoxide (DMSO) was added. The absorbance was measured at 540 nm using
a microtiter plate reader. For the cell viability visualization, HaCaT cells were pre-treated with or
without either NA (1 µM), NA–IVH (1 µM), or NAC (1 mM) for 2 h, and were the incubated with or
without 1 mM of H2O2 for 21 h. The media was discarded, then the cells were washed with PBS and
fixed using 95% (v/v) ethanol for 5 min. After fixation, the cells were washed with PBS and stained
using 2 mL 2% methylene blue solution for 1 min. An image was acquired at indicated time using
AxioObserver FL microscope at 10 and 20×magnification.
4.4. DPPH Radical Scavenging Assay
A DPPH (2,2-diphenyl-1-picrylhydrazyl) radical scavenging assay was used to determine the
radical scavenging effects of the antioxidant compounds [50,51]. The DPPH (Sigma-Aldrich, MO,
USA) solutions were prepared in ethanol as a stock solution, and diluted to 0.1 mM final working
concentration. Then, 0.1 mM DPPH solution was added to 0.5 mL of each sample, and the samples
were incubated at 4 ◦C for 30 min. After the reaction was complete, the absorbance was measured at
517 nm using a Multiskan Go Spectrophotometer (Thermo Fisher Scientific, MA, USA).
4.5. ROS Scavenging Assay
Intracellular ROS scavenging assays were performed by measuring the fluorescence
intensity of the 5-(and-6)-chloromethyl-2′,7′-dichlorodihydrofluorescein diacetate, acetyl ester probe,
which intensity is in accordance to the amount of ROS in presence. The HaCaT cells were pre-treated
with or without either DMSO, NA (1 µM), NA–IVH (1 µM), or NAC (1 mM) for 24 h, and were then
incubated with or without 1 mM of H2O2 for 2 h. The media was replaced with PBS containing 5 µM
of 5-(and-6)-chloromethyl-2′,7′-dichlorodihydrofluorescein diacetate, acetyl ester (CM-H2DCFDA;
Thermo Fisher Scientific, MA, USA) for 20 min, prior to detection. The images were captured using
a IX81 inverted microscope (Olympus, Tokyo, Japan) at 2 × magnification. The images acquired were
subjected to intensity measurement using Metamorph 6.1 software (Molecular Devices, Sunnyvale,
CA, USA).
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4.6. In Vitro Wound-Healing Assay
The cells were grown to confluence in 6-well plates and a scratch wound was created manually
using a P100 pipet tip [52]. The HaCaT cells were treated with or without either DMSO, NA (1 µM),
NA–IVH (1 µM), or EGF (30 ng/mL), for 24 h. The media was discarded and the cells were washed
with PBS. The image was acquired at the indicated time using the AxioObserver FL microscope
at 10× magnification. The width of the wound was measured in more than three locations
and the percentage of the healing area was indicated using Image J (ver.1.51J8, Wayne Rasband
National Institutes of Health, USA) software. The data was obtained from more than three
independent experiments.
4.7. Quantitative Real-Time PCR
The total RNA was isolated from cells using a TRIzol reagent (Invitrogen, Carlsbad, CA, USA).
The cDNAs were synthesized using a High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, Foster City, CA, USA), in accordance with the manufacturer’s instructions, then were
subjected to quantitative real-time PCR and transcription expression of the following genes that
were analyzed; CAT (F; 5′-CTGAGTCTCTGCATCAGGTTT-3′, R; 5′-TCATGTGGCGATGTCCAT-3′),
GP×1 (F; 5′-GCACCCTCTCTTCGCCTTC-3′, R; 5′-TCAGGCTCGATGTCAATGGTC-3′), Nrf2, (F;
5′-CAGGCTCAGTCACCTGAAACTTCT-3′, R; 5′-TCTCTGGTGTGTTCTCACATTGGG-3′), HO-1 (F;
5′-ACCCATGACACCAAGGACCAGA-3′, R; 5′-GTGTAAGGACCCATCGGAGAAGC-3′), SOD1 (F;
5′-ACGGTGGGCCAAAGGAT-3′, R; 5′-TCTTTGTCAGCAGTCACAATTGC-3′), SOD2 (F; 5′-AATC
AGGATCCACTGCAAGGA-3′, R; 5′-AGGCGTGCTCCCACACATC-3′), and SPTLC2 (F; 5′-GGAG
ATGCTGAAGCGGAAC-3′, R; 5′-GCTGCAATAGGTCCCCAACT-3′).
5. Statistical Analysis
The Prism 5.0 software was utilized for all of the statistical analyses. One-way analysis of variance
(ANOVA) or Student’s t-test was used to assess the difference between groups, and p < 0.05 was
regarded as a statistical significance difference.
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